- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Shoshana Lipson on the Patient Perception of CGRP Inhibitors
Shoshana Lipson, a patient advocate and founder of the “CGRP & Migraine Community ” on Facebook explains the patient perspective of CGRP inhibitors.
Shoshana Lipson, a patient advocate and founder of the “CGRP & Migraine Community ” on Facebook explains the patient perspective of CGRP inhibitors.
Transcript:
Are patients knowledgeable about [calcitonin gene-related peptide] CGRP inhibitors?
So, I would say it is kind of a mixed bag in terms of knowledge about the CGRP medications. Some people are very knowledgeable; they knew that they were coming, they had it planned, I personally had my doctor’s appointment set around a week after the first medication was approved. I knew it was coming and I knew I wanted to try it.
But then you’ve got people on the other end of the spectrum who are still saying “What? What’s CGRP and what does that stand for, what does it do, does this actually potentially help someone who has migraine?” So, we have the full range of the spectrum, and then again, trying to take that information and put it into simple language is just really, really crucial. So, we not only have my support group, but there are obviously also posts in the other migraine groups, but I’m also writing articles and speaking at different places just to educate patients about these new medications and also what they’re like in real-world application.
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
What the Updated Telephone Consumer Protection Act Rules Mean for Health Care Messaging
April 4th 2025As new Federal Communications Commission rules take effect April 11, 2025, mPulse CEO Bob Farrell explains how health organizations can stay compliant while building patient trust through transparency and personalized engagement.
Read More
High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment
April 4th 2025Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.
Read More
